atomoxetine hydrochloride has been researched along with Cardiovascular Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| de Vries, F; Houghton, R; Loss, G | 1 |
| Durand, M; Gow, R; Guertin, J; Holbrook, A; LeLorier, J; Levine, M | 1 |
| Alexander, ME; Babalola, R; Hammerness, PG; Karampahtsis, C | 1 |
| Allen, AJ; Escobar, R; Kryzhanovskaya, LA; Lane, JR; Lipsius, S; Tanaka, Y; Trzepacz, PT; Upadhyaya, H | 1 |
| Crystal, S; Gerhard, T; Huang, C; Olfson, M; Saidi, A; Winterstein, AG | 1 |
| Bilker, WB; Cziraky, MJ; Daniel, GW; Guevara, J; Hennessy, S; Kimmel, SE; Schelleman, H; Strom, BL | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Dittmann, RW; Döpfner, M; Graham, J; Hamilton, R; Hollis, C; Holtmann, M; Hulpke-Wette, M; Lecendreux, M; Rosenthal, E; Rothenberger, A; Santosh, P; Sergeant, J; Simonoff, E; Sonuga-Barke, E; Steinhausen, HC; Taylor, E; Wong, IC; Zuddas, A | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E | 1 |
| Arcieri, R; Bonati, M; Chiarotti, F; Germinario, EA; Masi, G; Panei, P; Vella, S; Zuddas, A | 1 |
| Livio, F | 1 |
| Forrester, MB | 1 |
| Coghill, D; Graham, J | 1 |
4 review(s) available for atomoxetine hydrochloride and Cardiovascular Diseases
| Article | Year |
|---|---|
Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Humans; Time Factors | 2015 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome | 2013 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydrochloride; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Fibrinolytic Agents; Fumarates; Hemorrhage; Humans; Pharmacovigilance; Propylamines | 2013 |
Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Clinical Trials as Topic; Growth Disorders; Humans; Mental Disorders; Nervous System Diseases; Propylamines | 2008 |
1 trial(s) available for atomoxetine hydrochloride and Cardiovascular Diseases
| Article | Year |
|---|---|
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Female; Heart Rate; Humans; Male; Time Factors; Treatment Outcome; Withholding Treatment | 2015 |
7 other study(ies) available for atomoxetine hydrochloride and Cardiovascular Diseases
| Article | Year |
|---|---|
Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Cardiovascular Diseases; Cardiovascular System; Case-Control Studies; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Female; Humans; Logistic Models; Male; Retrospective Studies | 2020 |
Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Studies; Central Nervous System Stimulants; Child; Drug Costs; Emergency Service, Hospital; Female; Health Services Accessibility; Hospitalization; Humans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Logistic Models; Male; Methylphenidate; Odds Ratio; Office Visits; Program Evaluation; Propylamines; Quebec; Risk Assessment; Risk Factors | 2014 |
Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Cohort Studies; Drug Utilization; Female; Humans; Insurance Claim Review; Logistic Models; Male; Middle Aged; Multivariate Analysis; Propylamines; Retrospective Studies; Young Adult | 2010 |
Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Cohort Studies; Databases, Factual; Humans; Methylphenidate; Myocardial Infarction; Propylamines; Research Design; United States | 2010 |
European guidelines on managing adverse effects of medication for ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Dosage Calculations; Drug Tolerance; Drug Utilization Review; Europe; Humans; Monitoring, Physiologic; Propylamines; Risk Assessment; Substance-Related Disorders; Suicide, Attempted | 2011 |
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Italy; Male; Methylphenidate; Propylamines; Prospective Studies; Registries | 2012 |
Adult atomoxetine ingestions reported to Texas Poison Control Centers, 2003-2005.
Topics: Adult; Aged; Atomoxetine Hydrochloride; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Poison Control Centers; Propylamines; Retrospective Studies; Suicide, Attempted; Texas | 2006 |